Literature DB >> 31209521

Prevalence of TTN mutations in patients with dilated cardiomyopathy : A meta-analysis.

H-J Fang1, B-P Liu2.   

Abstract

A meta-analysis was performed to assess the prevalence of TTN mutations in patients with dilated cardiomyopathy (DCM). Prevalence point estimates and 95% confidence intervals were computed using the logit transformation formula. The prevalence of TTN mutations in patient with DCM, familial dilated cardiomyopathy (FDCM), and sporadic dilated cardiomyopathy (SDCM) was 0.17 (95% CI: 0.14-0.19), 0.23 (95% CI: 0.20-0.26), and 0.16 (95% CI: 0.12-0.21), respectively. No individual study had a marked influence on the pooled prevalence in the meta-analysis. Meta-regression analysis between the logit event for prevalence and sample size explained 32% of between-study variance (p < 0.05). Cumulative meta-analysis confirmed the influence of sample size on the reported prevalence among the different studies. In conclusion, the present analysis suggests that TTN mutations are familial in DCM patients. More attention should be paid to TTN mutations in clinical examinations.

Entities:  

Keywords:  Cardiac muscle; Genes; Heart failure; Systematic review; Titin

Mesh:

Substances:

Year:  2019        PMID: 31209521     DOI: 10.1007/s00059-019-4825-4

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  2 in total

1.  Amino Acid-Level Signal-to-Noise Analysis Aids in Pathogenicity Prediction of Incidentally Identified TTN-Encoded Titin Truncating Variants.

Authors:  Patrick S Connell; Amy M Berkman; BriAnna M Souder; Elisa J Pirozzi; Julia J Lovin; Jill A Rosenfeld; Pengfei Liu; Hari Tunuguntla; Hugh D Allen; Susan W Denfield; Jeffrey J Kim; Andrew P Landstrom
Journal:  Circ Genom Precis Med       Date:  2020-11-23

Review 2.  Modifications of Titin Contribute to the Progression of Cardiomyopathy and Represent a Therapeutic Target for Treatment of Heart Failure.

Authors:  Charles Tharp; Luisa Mestroni; Matthew Taylor
Journal:  J Clin Med       Date:  2020-08-26       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.